1-10 of 10
Florence Raynaud
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Open Access
Elizabeth A. Coker, Adam Stewart, Bugra Ozer, Anna Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary O'Brien, Florence Raynaud, Johann de Bono, Bissan Al-Lazikani, Udai Banerji
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 1020–1029.
https://doi.org/10.1158/1535-7163.MCT-21-0442
Published: 01 June 2022
View articletitled, Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
Open the PDF for Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes in another window
Includes: Supplementary data
Journal Articles

Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.

Free
Andrew Moore, Amir Faisal, Vassilios Bavetsias, David Gonzalez de Castro, Chongbo Sun, Butrus Atrash, Melanie Valenti, Alexis de Haven Brandon, Sian Avery, Andrew Pearson, Paul Workman, Julian Blagg, Florence Raynaud, Suzanne Eccles, Spiros Linardopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B74.
https://doi.org/10.1158/1535-7163.TARG-11-B74
Published: 12 November 2011
View articletitled, Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.
Journal Articles

Characterization of CCT129202, a novel Aurora kinase inhibitor and in vivo quantification of biological activity

Free
Florence Chan, Chongbo Sun, Meg Perumal, Quang-De Nguyen, Vassilios Bavetsias, Edward McDonald, Vanessa Martins, Nicola Wilsher, Florence Raynaud, Melanie Valenti, Sue Eccles, Robert tePoele, Paul Workman, Eric Aboagye, Spyridon Linardopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A239.
Published: 01 November 2007
View articletitled, Characterization of CCT129202, a novel Aurora kinase inhibitor and in vivo quantification of biological activity
Journal Articles

Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC)

Free
Gerhardt Attard, Alison Reid, Rajesh Sinha, Rhoda Molife, Florence Raynaud, Mitch Dowsett, Mary Barrett, Emilda Thompson, Timothy Yap, Sarah Settatree, Vanessa Martins, Christopher Parker, David Dearnaley, Elizabeth Folkerd, Gloria Lee, Johann De Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B73.
Published: 01 November 2007
View articletitled, Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC)
Journal Articles

Cassette dosing in tumor bearing animals for the discovery of NVP-AUY922, a novel HSP90 inhibitor.

Free
Florence Raynaud, Angela Hayes, Vanessa Martins, Nicola Smith, Swee Sharp, Melanie Valenti, Alan Henley, Thomas Matthews, Kwai-Ming Cheung, Andrew Kalusa, Keith Jones, Karen James, Edward McDonald, Paul Brough, Andrew Massey, Brian Dymock, Martin Drysdale, Suzanne Eccles, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B289.
Published: 01 November 2007
View articletitled, Cassette dosing in tumor bearing animals for the discovery of NVP-AUY922, a novel HSP90 inhibitor.
Journal Articles

Characterization of a potent inhibitor of class 1 phosphatidylinositide-3’-kinases (PI3K) in human glioma

Free
Paul Clarke, Sandrine Guillard, Francesca Di Stefano, Robert te Poele, Melanie Valenti, Alexis de Haven Brandon, Sue Eccles, Florence Raynaud, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A243.
Published: 01 November 2007
View articletitled, Characterization of a potent inhibitor of class 1 phosphatidylinositide-3’-kinases (PI3K) in human glioma
Journal Articles

A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors

Free
Simon Pacey, Richard Wilson, Mike Walton, Eatock Martin, Javier Moreno-Farre, Hendrik-Tobias Arkenau, Heidi Steinfeldt, Florence Raynaud, Paul Workman, Ian Judson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): PR-6.
Published: 01 November 2007
View articletitled, A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors
Journal Articles

NVP-AUY922 / VER-52296: A novel 3,4 diarylisoxazole Hsp90 chaperone inhibitor discovered via structure-based drug design

Free
Paul Brough, Andrew Massey, Martin Drysdale, Xavier Barril, Brian Dymock, Suzanne Eccles, Harry Finch, Rod Hubbard, Edward McDonald, Florence Raynaud, Swee Sharp, Alan Surgenor, Mike Wood, Paul Workman, Lisa Wright
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B281.
Published: 01 November 2007
View articletitled, NVP-AUY922 / VER-52296: A novel 3,4 diarylisoxazole Hsp90 chaperone inhibitor discovered via structure-based drug design
Journal Articles

NVP-AUY922, a novel diarylisoxazole resorcinol HSP90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts

Free
Suzanne Eccles, Swee Sharp, Florence Raynaud, Melanie Valenti, Lisa Patterson, Sharon Gowan, Kathy Boxall, Wynne Aherne, Martin Rowlands, Angela Hayes, Vanessa Martins, Federique Urban, Chrisostomos Prodromou, Laurence Pearl, Karen James, Thomas Matthews, Kwai-Ming Cheung, Andrew Kalusa, Keith Jones, Edward McDonald, Paul Brough, Andrew Massey, Brian Dymock, Martin Drysdale, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B284.
Published: 01 November 2007
View articletitled, NVP-AUY922, a novel diarylisoxazole resorcinol HSP90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts
Journal Articles

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

Free
Swee Y. Sharp, Chrisostomos Prodromou, Kathy Boxall, Marissa V. Powers, Joanna L. Holmes, Gary Box, Thomas P. Matthews, Kwai-Ming J. Cheung, Andrew Kalusa, Karen James, Angela Hayes, Anthea Hardcastle, Brian Dymock, Paul A. Brough, Xavier Barril, Julie E. Cansfield, Lisa Wright, Allan Surgenor, Nicolas Foloppe, Roderick E. Hubbard, Wynne Aherne, Laurence Pearl, Keith Jones, Edward McDonald, Florence Raynaud, Sue Eccles, Martin Drysdale, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (4): 1198–1211.
https://doi.org/10.1158/1535-7163.MCT-07-0149
Published: 12 April 2007
View articletitled, Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Open the PDF for Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues in another window
Includes: Supplementary data